Abstract 648P
Background
No validated preoperative prognostic markers exist for pts with resectable gastric/GOJ adenocarcinoma (AC). There is evidence that NLR and platelet-to-lymphocyte ratio (PLR) predict outcomes in different types of malignancies. We aimed to explore the prognostic significance of NLR in pts with resectable gastric/GOJ AC undergoing perioperative chemotherapy.
Methods
In this retrospective cohort study, baseline neutrophil, lymphocyte and platelet blood count levels were recorded for all pts with resectable gastric/GOJ AC commenced on neoadjuvant ECX-based chemotherapy (Jul'09-Dec'14). The prognostic significance of baseline characteristics and blood count levels on overall survival (OS) and tumour resectability was tested by Cox-regression analysis. All comparisons were two-sided with level of significance p
Results
Of 368 pts included, 95 pts (26%) had gastric and 273 (74%) had GOJ primaries. ECOG Performance status (PS) was 0 in 133 (36%) and 1-2 in 235 pts (64%); 294 pts (80%) had curative surgery. After a median follow-up of 42 months (mo) (range 0.5-77) 209 (57%) pts were deceased. Increasing NLR associated with shorter OS (HR = 1.13, 95%CI = 1.06-1.19, p
Conclusions
NLR is highly prognostic in pts with resectable gastric/GOJ AC undergoing neoadjuvant ECX chemotherapy. We propose a baseline prognostic model that might inform prognosis and aid stratification of pts in clinical trials.
Clinical trial identification
n/a
Legal entity responsible for the study
The Christie NHS Foundation Trust
Funding
The Christie NHS Foundation Trust
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
ZUMA-3: A phase 1/2 multi-center study evaluation the safety and efficacy of KTE-C19 anti-CD19 CAR T cells in adult patients with relapsed/refractory B precursor acute lymphoblastic leukemia (R/R ALL)
Presenter: Bijal Shah
Session: Poster display
Resources:
Abstract
ZUMA-2: A phase 2 multi-center study evaluating the efficacy of KTE-C19 (Anti-CD19 CAR T cells) in patients with relapsed/refractory Mantle cell lymphoma (R/R MCL)
Presenter: Michael Wang
Session: Poster Display
Resources:
Abstract
ZUMA-1: A phase 2 multi-center study evaluating anti-CD19 chimeric antigen receptor (CAR) T cells in patients with refractory aggressive non-Hodgkin lymphoma (NHL)
Presenter: Sattva Neelapu
Session: Poster Display
Resources:
Abstract
Younger age as a prognostic indicator in breast cancer: Correlation between clinical-pathologic factors and miRNAs and long-term follow-up
Presenter: Maria Teresa Martinez
Session: Poster display
Resources:
Abstract
Window study of the PARP inhibitor rucaparib in patients with primary triple negative or BRCA1/2 related breast cancer (RIO)
Presenter: Christy Toms
Session: Poster display
Resources:
Abstract
Whole exome sequencing (WES) and RNA sequencing (RNA-seq) in routine clinical practice for colorectal cancer (CRC) and non-small cell lung cancer (NSCLC) patients (pts)
Presenter: Géraldine Perkins
Session: Poster display
Resources:
Abstract
What is the optimal annual interpretive volume for a radiologist reading screening mammograms?
Presenter: Asli Uluturk
Session: Poster display
Resources:
Abstract
What decides breast conservation versus mastectomy in the background of diverse sociocultural environment, an Indian study
Presenter: Poonamalle Padmanabhan Bapsy
Session: Poster display
Resources:
Abstract
Waiting time to diagnosis and treatment of the head and neck cancer in four institutions in Portugal
Presenter: Ana Castro
Session: Poster display
Resources:
Abstract
Wait times for diagnosis and treatment of lung cancer: a single centre experience
Presenter: Catherine Labbe
Session: Poster Display
Resources:
Abstract